Get the Stockscreener App
291.68
3.77%
-11.44
Penumbra Inc stock is traded at $291.68, with a volume of 612.20K.
It is down -3.77% in the last 24 hours and up +8.75% over the past month.
Penumbra Inc develops and manufactures medical devices for the neurovascular and peripheral vascular markets. Its products are sold to hospitals and are developed for use by specialist physicians. Within the neurovascular business, the firm offers products for neurovascular access, ischemic stroke, neurovascular embolization, and neurosurgical tool markets. In the peripheral vascular business, the firm sells devices related to peripheral embolization and peripheral thrombectomy. It operates as one reportable segment and its business activity consists of the design, development, manufacturing and marketing of inventive medical products.
See More
Previous Close:
$303.12
Open:
$303
24h Volume:
612.20K
Relative Volume:
1.51
Market Cap:
$11.23B
Revenue:
$1.16B
Net Income/Loss:
$34.55M
P/E Ratio:
339.16
EPS:
0.86
Net Cash Flow:
$134.18M
1W Performance:
+8.56%
1M Performance:
+8.75%
6M Performance:
+49.42%
1Y Performance:
+12.92%
1-Day Range:
$290.55
$304.11
1-Week Range:
$264.81
$310.00
52-Week Range:
$148.00
$310.00
Penumbra Inc Stock (PEN) Company Profile
Name
Penumbra Inc
Sector
Industry
Phone
(510) 995-2486
Address
ONE PENUMBRA PLACE, ALAMEDA, CA
Compare PEN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PEN
Penumbra Inc
|
291.68 | 11.23B | 1.16B | 34.55M | 134.18M | 0.86 |
|
ABT
Abbott Laboratories
|
134.92 | 234.01B | 41.95B | 13.40B | 6.49B | 7.65 |
|
BSX
Boston Scientific Corp
|
104.49 | 154.20B | 16.75B | 1.85B | 2.37B | 1.25 |
|
SYK
Stryker Corp
|
382.78 | 146.06B | 22.60B | 2.99B | 3.49B | 7.76 |
|
MDT
Medtronic Plc
|
89.94 | 115.42B | 33.20B | 4.26B | 5.47B | 3.29 |
|
EW
Edwards Lifesciences Corp
|
73.30 | 43.23B | 5.72B | 4.17B | 490.10M | 6.97 |
Penumbra Inc Stock (PEN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-21-25 | Initiated | UBS | Buy |
| Dec-17-24 | Initiated | Oppenheimer | Outperform |
| Dec-11-24 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Sep-18-24 | Initiated | Stifel | Buy |
| Sep-03-24 | Initiated | Leerink Partners | Outperform |
| Jul-31-24 | Downgrade | Citigroup | Buy → Neutral |
| Jul-31-24 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Feb-23-24 | Downgrade | JP Morgan | Overweight → Neutral |
| Sep-06-23 | Initiated | Morgan Stanley | Equal-Weight |
| Jul-19-23 | Initiated | Robert W. Baird | Outperform |
| Mar-29-23 | Downgrade | Needham | Buy → Hold |
| Jan-30-23 | Initiated | Piper Sandler | Overweight |
| Nov-04-22 | Upgrade | Citigroup | Neutral → Buy |
| Oct-12-22 | Initiated | Jefferies | Buy |
| Oct-05-22 | Downgrade | Citigroup | Buy → Neutral |
| Sep-09-22 | Upgrade | Needham | Hold → Buy |
| Jul-18-22 | Initiated | RBC Capital Mkts | Outperform |
| Apr-19-22 | Initiated | Deutsche Bank | Buy |
| Mar-08-22 | Initiated | Needham | Hold |
| Sep-16-21 | Initiated | Truist | Buy |
| Jun-04-21 | Upgrade | BTIG Research | Neutral → Buy |
| Dec-16-20 | Downgrade | BTIG Research | Buy → Neutral |
| Oct-07-20 | Resumed | Canaccord Genuity | Buy |
| Sep-29-20 | Initiated | BTIG Research | Buy |
| Sep-08-20 | Downgrade | BofA Securities | Buy → Neutral |
| Mar-05-20 | Initiated | Citigroup | Buy |
| Jun-13-19 | Reiterated | BofA/Merrill | Buy |
| May-30-19 | Upgrade | JP Morgan | Neutral → Overweight |
| May-21-19 | Initiated | William Blair | Outperform |
| Oct-29-18 | Resumed | BofA/Merrill | Buy |
| Oct-08-18 | Initiated | RBC Capital Mkts | Outperform |
| Feb-21-18 | Initiated | William Blair | Outperform |
| Jan-02-18 | Downgrade | JP Morgan | Overweight → Neutral |
| Nov-30-15 | Reiterated | Canaccord Genuity | Buy |
| Oct-13-15 | Initiated | Wells Fargo | Outperform |
View All
Penumbra Inc Stock (PEN) Latest News
Penumbra, Inc. Just Missed EarningsBut Analysts Have Updated Their Models - Yahoo Finance
Penumbra Inc. Faces Financial Peril Amid Rising Customer Payment Defaults - TipRanks
Penumbra price target raised to $320 from $305 at UBS - TipRanks
Penumbra Announces Don Kassing Will Retire From Board Of Directors -February 21, 2025 at 05:50 pm EST - Marketscreener.com
Penumbra Announces Board Transition with Kassing’s Retirement - TipRanks
Leadership Shift at Penumbra: How Will 17-Year Board Veteran's Exit Shape Corporate Governance? - StockTitan
Penumbra targets 13%-14% revenue growth for 2025 with focus on thrombectomy market expansion - MSN
Neuro-interventional Devices Market Growth in Future Scope - openPR
Penumbra (PEN) Upgraded to Buy: Here's Why - Yahoo Finance
Why Penumbra (PEN) Stock Is Trading Up Today - MSN
Here's What Key Metrics Tell Us About Penumbra (PEN) Q4 Earnings - MSN
Penumbra Inc. Earnings Call Reveals Strong U.S. Growth - TipRanks
Stroke Device Maker Penumbra Stock Surges On Earnings Beat, Analysts Boost Price Forecasts After Upbeat 2025 Outlook - Benzinga
Why Penumbra (PEN) Stock Is Trading Up Today By Stock Story - Investing.com Canada
UBS raises Penumbra stock price target to $320, keeps buy rating - Investing.com
Penumbra stock hits 52-week high, reaches $296.1 - Investing.com India
Penumbra stock hits 52-week high, reaches $296.1 By Investing.com - Investing.com Nigeria
Truist Securities Raises Price Target on Penumbra to $325 From $285, Keeps Buy Rating - Marketscreener.com
Penumbra, Inc. (NYSE:PEN) Q4 2024 Earnings Call Transcript - Insider Monkey
Penumbra price target raised to $340 from $323 at Canaccord - TipRanks
Compass, Penumbra, Bumble - TradingView
Deutsche Bank Adjusts Penumbra Price Target to $326 From $241, Maintains Buy Rating - Marketscreener.com
Penumbra Q4 Earnings & Revenues Top, Margins Expand, Stock Rises - Yahoo Finance
Penumbra price target raised to $330 from $250 at Piper Sandler - TipRanks
Penumbra Inc earnings beat by $0.07, revenue topped estimates - Investing.com Nigeria
Axsome Therapeutics, Penumbra, Republic Services - TradingView
Penumbra Inc (PEN) Q4 2024 Earnings Call Highlights: Strong Revenue Growth Amid International ... - Yahoo Finance
Penumbra Inc (PEN) Q4 2024 Earnings Call Highlights: Strong Revenue Growth Amid International ... By GuruFocus - Investing.com Canada
Penumbra: Q4 Earnings Snapshot - The Advocate
Penumbra, Inc. Reports Strong 2024 Financial Performance - TipRanks
Penumbra (PEN) Beats Q4 Earnings and Revenue Estimates - MSN
Penumbra’s Impressive Revenue Sparks Stock Reactions - TipRanks
Earnings call transcript: Penumbra Q4 2024 beats expectations, stock surges - Investing.com
Penumbra Inc Q4 2024 Earnings: Revenue Surpasses Estimates at $3 - GuruFocus.com
Earnings call transcript: Penumbra Q4 2024 beats expectations, stock surges By Investing.com - Investing.com UK
Penumbra Inc SEC 10-K Report - TradingView
Penumbra's Q4 earnings beat lifts stock 3.2% By Investing.com - Investing.com Canada
Penumbra’s Q4 earnings beat lifts stock 3.2% By Investing.com - Investing.com Nigeria
Penumbra's Q4 earnings beat lifts stock 3.2% - Investing.com
Earnings Flash (PEN) PENUMBRA INC. Posts Q4 Revenue $315.5M, vs. FactSet Est of $311.4M - Marketscreener.com
Penumbra’s (NYSE:PEN) Q4 Sales Beat Estimates - Yahoo Finance
Penumbra, Inc. Reports Fourth Quarter and Full Year 2024 Financial Results - PR Newswire
Penumbra (PEN) Reports Q4: Everything You Need To Know Ahead Of Earnings - The Globe and Mail
Penumbra Inc. Set to Announce Earnings Amidst Market InterestNews and Statistics - IndexBox, Inc.
Penumbra (PEN) Reports Q4: Everything You Need To Know Ahead Of Earnings By Stock Story - Investing.com Canada
PENUMBRA Earnings Preview: Recent $PEN Insider Trading, Hedge Fund Activity, and More - Nasdaq
Allspring Global Investments Holdings LLC Grows Stock Holdings in Penumbra, Inc. (NYSE:PEN) - MarketBeat
Penumbra, Inc. (NYSE:PEN) Short Interest Update - MarketBeat
Penumbra (PEN) to Release Quarterly Earnings on Tuesday - MarketBeat
WCM Investment Management LLC Makes New Investment in Penumbra, Inc. (NYSE:PEN) - MarketBeat
Spotting Winners: Penumbra (NYSE:PEN) And Medical Devices & SuppliesCardiology, Neurology, Vascular Stocks In Q3 - Yahoo Finance
Penumbra Inc Stock (PEN) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.16%
0.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):